IDH2 and astrocytoma (excluding glioblastoma): The shorter OS may be partly due to the exclusion of IDH-mutant astrocytomas with relatively better survival and the introduction of mol-GBMs that are more infiltrative and less responsive to TMZ chemotherapy.